Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

GLP-2 Dysregulates Hepatic Lipoprotein Metabolism, Inducing Fatty Liver and VLDL Overproduction in Male Hamsters and Mice.

Endocrinology | 2018

Fundamental complications of insulin resistance and type 2 diabetes include the development of nonalcoholic fatty liver disease and an atherogenic fasting dyslipidemic profile, primarily due to increases in hepatic very-low-density lipoprotein (VLDL) production. Recently, central glucagon-like peptide-2 receptor (GLP2R) signaling has been implicated in regulating hepatic insulin sensitivity; however, its role in hepatic lipid and lipoprotein metabolism is unknown. We investigated the role of glucagon-like peptide-2 (GLP-2) in regulating hepatic lipid and lipoprotein metabolism in Syrian golden hamsters, C57BL/6J mice, and Glp2r-/- mice consuming either a normal chow or high-fat diet (HFD). In the chow-fed hamsters, IP GLP-2 administration significantly increased fasting dyslipidemia, hepatic VLDL production, and the expression of key genes involved in hepatic de novo lipogenesis. In HFD-fed hamsters and chow-fed mice, GLP-2 administration exacerbated or induced hepatic lipid accumulation. HFD-fed Glp2r-/- mice displayed reduced glucose tolerance, VLDL secretion, and microsomal transfer protein lipid transfer activity, as well as exacerbated fatty liver. Thus, we conclude that GLP-2 plays a lipogenic role in the liver by increasing lipogenic gene expression and inducing hepatic steatosis, fasting dyslipidemia, and VLDL overproduction. In contrast, the lack of Glp2r appears to interfere with VLDL secretion, resulting in enhanced hepatic lipid accumulation. These studies have uncovered a role for GLP-2 in maintaining hepatic lipid and lipoprotein homeostasis.

Pubmed ID: 30052880 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


MTP (antibody)

RRID:AB_2734119

This polyclonal targets MTP

View all literature mentions

Phospho-AMPKα (Thr172) Antibody (antibody)

RRID:AB_330330

This polyclonal targets Phospho-AMPKα (Thr172)

View all literature mentions

Phospho-Acetyl-CoA Carboxylase (Ser79) Antibody (antibody)

RRID:AB_330337

This polyclonal targets Phospho-Acetyl-CoA Carboxylase (Ser79)

View all literature mentions

Anti-β-Actin Antibody (antibody)

RRID:AB_476744

This monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH

View all literature mentions

Fatty Acid Synthase Antibody (antibody)

RRID:AB_10002181

This unknown targets Fatty Acid Synthase

View all literature mentions

Acetyl-CoA Carboxylase Antibody (antibody)

RRID:AB_2219400

This polyclonal targets Acetyl CoA Carboxylase

View all literature mentions

SREBP-1 (K-10) (antibody)

RRID:AB_2194226

This polyclonal targets SREBP-1 (K-10)

View all literature mentions

Apolipoprotein B (antibody)

RRID:AB_2734118

This polyclonal targets ApoB

View all literature mentions

MTP (antibody)

RRID:AB_2734119

This polyclonal targets MTP

View all literature mentions